BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 10589362)

  • 41. Early rheumatoid arthritis in a patient with Sjögren's syndrome and pulmonary nodular amyloidosis: clinical implication of early limited use of infliximab.
    Mori S; Koga Y; Imamura F; Cho I; Sugimoto M
    Mod Rheumatol; 2007; 17(6):500-6. PubMed ID: 18084704
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
    Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.
    Durez P; Malghem J; Nzeusseu Toukap A; Depresseux G; Lauwerys BR; Westhovens R; Luyten FP; Corluy L; Houssiau FA; Verschueren P
    Arthritis Rheum; 2007 Dec; 56(12):3919-27. PubMed ID: 18050189
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment.
    Kim J; Ryu H; Yoo DH; Park SH; Song GG; Park W; Cho CS; Song YW
    J Korean Med Sci; 2013 Dec; 28(12):1716-22. PubMed ID: 24339699
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New disease modifying agents in adult rheumatoid arthritis.
    Koh ET
    Ann Acad Med Singap; 2001 Mar; 30(2):170-3. PubMed ID: 11379415
    [TBL] [Abstract][Full Text] [Related]  

  • 49. "Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate.
    Hochberg MC; Tracy JK; Flores RH
    Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii51-4. PubMed ID: 11890654
    [No Abstract]   [Full Text] [Related]  

  • 50. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
    Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
    Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
    Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
    Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis.
    Visvanathan S; Marini JC; Smolen JS; Clair EW; Pritchard C; Shergy W; Pendley C; Baker D; Bala M; Gathany T; Han J; Wagner C
    J Rheumatol; 2007 Jul; 34(7):1465-74. PubMed ID: 17552048
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis.
    Yazici Y; Yazici H
    Clin Exp Rheumatol; 2008; 26(3):449-52. PubMed ID: 18578967
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Furst D; Weisman MH; St Clair EW; Keenan GF; van der Heijde D; Marsters PA; Lipsky PE;
    Arthritis Rheum; 2004 Apr; 50(4):1051-65. PubMed ID: 15077287
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study.
    Lan JL; Chou SJ; Chen DY; Chen YH; Hsieh TY; Young M
    J Formos Med Assoc; 2004 Aug; 103(8):618-23. PubMed ID: 15340661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
    Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Breedveld FC; Dijkmans BA;
    Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-77-82. PubMed ID: 17083767
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Infliximab: a review of its use in the management of rheumatoid arthritis.
    Markham A; Lamb HM
    Drugs; 2000 Jun; 59(6):1341-59. PubMed ID: 10882166
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.
    Keystone EC; Genovese MC; Hall S; Bae SC; Han C; Gathany TA; Xu S; Zhou Y; Leu JH; Hsia EC
    J Rheumatol; 2016 Feb; 43(2):298-306. PubMed ID: 26669912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.